Business Wire

Prometheus Fuels Hits Major Commercial Milestone

10.7.2025 16:00:00 EEST | Business Wire | Press release

Share

Prometheus Fuels (Prometheus), the company making low-cost carbon-neutral fuels from direct air capture and renewable electricity, today announced it has reached commercial readiness for its proprietary e-Fuel production system. The company’s Titan Forge Alpha prototype has successfully integrated a full-scale 50-cell Faraday Reactor validating its core technology at TRL 9, the highest benchmark for real-world deployment and system maturity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250710099048/en/

Prometheus Fuels' Titan Forge Alpha prototype has successfully integrated a full-scale 50-cell Faraday Reactor validating its core technology at TRL 9, the highest benchmark for real-world deployment and system maturity. With this milestone, Prometheus becomes the only company capable of producing low-cost carbon-neutral e-Fuel using direct air capture (DAC) and intermittent renewable energy, fully off-grid.

With this milestone, Prometheus becomes the only company capable of producing low-cost carbon-neutral e-Fuel using direct air capture (DAC) and intermittent renewable energy, fully off-grid. The company also stands apart from other e-fuel producers in not needing subsidies or hydrogen. Its Titan Forge Alpha plant, the world’s first operational DAC synthetic fuel facility, is already generating e-methanol from air and solar power.

Next up: Titan Fuel Forge One, the company’s first commercial-scale fuel production system. It will use the same proven stack architecture and kick off a new era of production for Prometheus. To date, the company has pre-sold more than 11 million tons of e-Fuel to be delivered over the next decade, reflecting strong demand from global energy buyers and deep market confidence in the company’s technology.

The Faraday Reactor, a hydrocarbon electrolyzer that converts CO2 from an integrated DAC tower directly to fuel, is core to Prometheus’ system. Designed to operate on variable power inputs, the system thrives in remote, off-grid environments where wind and solar energy are abundant, unlocking low-cost, distributed fuel production at a global scale.

“This milestone marks a turning point, not just for Prometheus, but for the future of energy,” said Rob McGinnis, founder and CEO of Prometheus. “We’ve invented and built an integrated DAC and fuel synthesis system that captures carbon from the air, runs on renewable energy, and produces e-Fuels that cost less than fossil at scale. It’s the kind of innovation that doesn’t just move the needle, it resets the standard. After years of development and validation, we’re now ready to scale and meet the world’s growing demand for energy.”

As AI workloads surge and data centers multiply, demand is rising for reliable, around-the-clock clean power. Solar is now the cheapest form of energy in the world, but its full potential has been limited by challenges in capture, transport, and storage. Batteries and grid infrastructure can’t fully solve the problem — especially in remote, fast-growing, or under-connected regions.

Prometheus’ patented technology turns cheap, abundant solar power into carbon-neutral fuel that works as firm, dispatchable baseload energy. It can be stored indefinitely, delivered anywhere without new transmission lines, and used to stabilize grids, power AI and data centers, and fuel global demand for steady, low-cost clean energy.

“We knew we had to be able to beat fossil fuels on cost from the beginning and that’s what we’ve achieved,” McGinnis added. “We don’t need subsidies, we don’t need hydrogen, we don’t need biogenic point-source CO2, and we don’t need the grid. We can turn the lowest cost energy in the world from solar in the best locations into liquid fuels that can meet the fast-growing need for new power. We’re ready to scale to meet real demand.”

The company’s core technology is patent-protected and has undergone third-party technical validation in preparation for full-scale commercial deployment. To see a demo of Prometheus fuel powering the company’s 1968 Mustang Fastback, the “Promethean Stang,” visit: https://bit.ly/Promethean-Stang-Reveal. To learn more about Prometheus visit: https://prometheusfuels.com/.

About Prometheus Fuels

Prometheus is the global leader in carbon-neutral fuels made from direct air capture and renewable electricity to power AI data centers, factories, ships, vehicles, and aircraft. The company’s patented technology produces fuel at fossil fuel prices without subsidies, transforming energy production. Designed to run off-grid, Prometheus offers a scalable source of new power, transforming intermittent renewable energy into firm dispatchable 24/7 power, anywhere it is needed. Backed by top-tier investors including Maersk, BMW, Y Combinator, Paul Graham, Jaan Tallinn, John and Patrick Collison, Garrett Camp, and Tom Preston-Werner, Prometheus is redefining the future of energy. Learn more at prometheusfuels.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250710099048/en/

Contacts

Media Contact:
Nickell Communications for Prometheus Fuels:
prometheus@nickellcommunications.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye